Pharma, Bio & Medical

Entries on Korean listed drugmakers, biotech, medical devices and healthcare services — earnings, orders, shareholder returns and valuation, read from public disclosures. Not investment advice.

Equity Journal

Yuhan Corporation Stock: A Record Quarter, 12% Recurring
ByEquity August 10, 2026September 17, 2026

I ran two divisions before I wrote anything about Yuhan Corporation stock.

Read More Yuhan Corporation Stock: A Record Quarter, 12% Recurring
Equity Journal

Alteogen Stock: The 2% Royalty That Capped a KOSDAQ Leader
ByEquity August 5, 2026September 17, 2026

Two percent. That single number erased billions of dollars of market value in one session on January 21, 2026, and…

Read More Alteogen Stock: The 2% Royalty That Capped a KOSDAQ Leader
Equity Journal

Celltrion Stock: Record Earnings, 52-Week Low. Why I’m Buying
ByEquity July 18, 2026September 17, 2026

The 30-second version. Celltrion stock is in a strange spot. The company just posted its best quarter ever — Q1 202…

Read More Celltrion Stock: Record Earnings, 52-Week Low. Why I’m Buying
Equity Journal

Samsung Biologics Stock: Why I Watch Valuation, Not Tariffs
ByEquity July 16, 2026September 17, 2026

Let me be honest about the framing. When people look at Samsung Biologics stock right now, they reach for two thing…

Read More Samsung Biologics Stock: Why I Watch Valuation, Not Tariffs